Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

Paolo Ciracì(University of Pisa), Vittorio Studiale(University of Pisa), Ada Taravella(University of Pisa), Carlotta Antoniotti(University of Pisa), Chiara Cremolini(University of Pisa)

Nature Reviews Clinical Oncology

November 18, 2024

10.1038/s41571-024-00965-0

Cited by 25

Abstract

Related Papers

The National Comprehensive Cancer Network

William T. McGivney|Cancer|1998|16.9k

The consensus molecular subtypes of colorectal cancer

Justin Guinney, Rodrigo Dienstmann, Xin Wang et al.|Nature Medicine|2015|5.2k

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al.|Journal of Clinical Oncology|2007|2k

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor et al.|Nature|2012|1.9k

Cetuximab for the Treatment of Colorectal Cancer

Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis et al.|New England Journal of Medicine|2007|1.8k